U.S. Global Investors, Inc. — Form 10-Q Summary
Business Context and Reporting Period
U.S. Global Investors, Inc. provides investment management services to exchange-traded funds and U.S. Global Investors Funds and invests corporate capital. This filing covers the three months ended September 30, 2023, the company’s fiscal first quarter of fiscal 2024, although the request identifies the period as 2023 Q1. The filing was signed December 14, 2023.
Financial Performance and Position
| Metric | Q1 Fiscal 2024 | Prior Comparable Quarter |
|---|---|---|
| Operating revenue | $3.133 million | $4.412 million |
| Operating income | $215,000 | $1.585 million |
| Net investment income (loss) | $(513,000) | $(1.460) million |
| Income (loss) before taxes | $(241,000) | $186,000 |
| Net income (loss) | $(176,000) | $53,000 |
| Basic and diluted EPS | $(0.01) | $0.00 |
| Cash flow from operations | $884,000 | $1.175 million |
- Advisory fees were $3.103 million, down 29.1%; administrative services fees were $30,000.
- Operating expenses increased 3.2% to $2.918 million, primarily because employee compensation increased 8.4% to $1.274 million.
- Total assets were $54.092 million and shareholders’ equity was $50.701 million at September 30, 2023.
- Cash and cash equivalents were $26.849 million; including restricted cash, total cash was $27.849 million.
- Net working capital was approximately $37.7 million and the current ratio was 14.3 to 1.
- The company had no borrowings outstanding under its $1 million credit facility, which was collateralized by $1 million of restricted cash.
- Investments carried at recurring fair value totaled $18.3 million, including $6.3 million of HIVE convertible debentures and approximately $11.9 million of equity securities.
- Investment management assets under management were approximately $1.8 billion at September 30, 2023, versus $2.3 billion a year earlier. Average assets under management declined to $2.1 billion from $2.9 billion.
Material Changes Versus the Prior Comparable Period
- Revenue declined $1.3 million, or 29.0%, primarily because lower ETF average assets reduced unitary management fees by approximately $1.2 million.
- Operating income declined $1.370 million as revenue decreased while operating expenses increased.
- Net investment loss improved by approximately $947,000, principally because unrealized equity losses and foreign-currency losses were lower than in the prior-year quarter. This improvement was partly offset by $818,000 of realized equity losses, primarily related to an impairment.
- The company moved from net income of $53,000 to a net loss of $176,000 despite a $65,000 tax benefit, compared with $133,000 of tax expense in the prior period.
- Cash increased $1.448 million during the quarter, supported by operating cash flow of $884,000, $750,000 of principal repayments on investments, and $800,000 of investment-sale proceeds. Uses included $611,000 of share repurchases and $326,000 of dividends.
- The company repurchased 198,213 Class A shares for $611,000, compared with 39,965 shares for $133,000 in the prior-year quarter.
- Shareholders’ equity declined $1.5 million, or 2.9%, primarily due to share repurchases, dividends, the new credit-loss accounting adoption, other comprehensive loss, and the quarterly net loss.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing provides no formal earnings or revenue guidance. Management expects current cash, investments, and available financing to meet foreseeable operating needs.
- The monthly dividend was maintained at $0.0075 per share through March 2024, subject to future Board approval. Dividend payments remain discretionary.
- The company adopted ASU 2016-13, the CECL credit-loss standard, on July 1, 2023. Adoption reduced retained earnings by $183,000 after tax and established a $232,000 initial allowance for one held-to-maturity debt security. The allowance was $205,000 at quarter-end.
- The HIVE-related investments are subject to significant cryptocurrency and equity-market volatility. The company reported $6.3 million of HIVE convertible debentures and $4,000 of HIVE warrants at quarter-end. HIVE valuation uses Level 3 models with significant unobservable inputs.
- Investment values and earnings may be affected by equity prices, interest rates, foreign-currency movements, cryptocurrency-related volatility, inflation, geopolitical events, market disruptions, and changes in assets under management.
- The company’s investment advisory agreements with USGIF were renewed through September 2024, and the U.S.-based ETF advisory agreement was renewed through July 2024.
- Fee waivers and expense reimbursements totaled $35,000 for SEA and $253,000 for USGIF during the quarter. Certain contractual expense limits run through April 2024.
- The company revised the prior-year quarter’s financial statements for an immaterial income-tax accounting error. The revision reduced previously reported prior-year net income from $107,000 to $53,000 and increased tax expense by $54,000.
- Management concluded that disclosure controls and procedures were not effective as of September 30, 2023 because material weaknesses in internal control over financial reporting remained from the fiscal 2023 Form 10-K.
- No material litigation accruals were recorded, excluding the reserve for uncertain tax positions. The company maintained a $530,000 reserve for uncertain tax positions.
Important Facts for Investors to Verify
- Confirm the remediation status and nature of the material weaknesses in internal control over financial reporting.
- Monitor assets under management, ETF flows, and fee rates because advisory revenue is primarily asset-based and declined materially year over year.
- Review the valuation assumptions and concentration risk associated with the HIVE Level 3 convertible debentures and warrants.
- Assess the sustainability of dividends and share repurchases against recurring operating earnings and cash flow.
- Verify the renewal of the $1 million credit facility before its May 31, 2024 expiration.
- Evaluate the impact of continuing fee waivers and expense reimbursements on advisory-service margins.
- Review the CECL allowance and the credit quality of the company’s unrated held-to-maturity debt security.